EksoNR receives FDA clearance for acquired brain injury rehabilitation
Ekso Bionics received FDA 510(k) clearance for EksoNR use in rehabilitation of patients with acquired brain injury.
Evidence notes
- The clearance expanded EksoNR beyond earlier stroke and spinal cord injury indications.
- The system is a robotic exoskeleton used in clinical rehabilitation settings.
- The approval supports EksoNR's path toward fielded use in robot manipulation, haptics or human-assistive robotics workflows.
Company context
Ekso Bionics develops wearable robotic exoskeletons for rehabilitation, mobility assistance and industrial use cases. Its systems use powered assistance to support human movement rather than replacing the worker or patient with a standalone robot.